{"id":"norepinephrine-ascorbic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Tissue necrosis at infusion site"},{"rate":null,"effect":"Anxiety / restlessness"}]},"_chembl":{"chemblId":"CHEMBL5087452","moleculeType":"Unknown","molecularWeight":"337.28"},"_dailymed":{"setId":"f13a92ec-bb94-4ebd-acaa-b9ad14d67cac","title":"BIOPHENOLICS (ACETYLCHOLINE CHLORIDE, ACETALDEHYDE, APIOLUM, ASCORBIC ACID, BHT, CAFFEIC ACID, CANDIDA ALBICANS, CHLOROGENIC ACID, CINNAMIC ACID, CONIFERYL ALCOHOL, COUMARIN, DOPAMINE, ESTROGEN, GABA, GALLIC ACID, HISTAMINE, INDOLE, L-DOPA, MALVIN, MANNAN, MELATONIN, MENADIONE, NOREPINEPHRINE, OCTOPAMINE, PHENYLALANINE, PHENYLI-SOTHIOCYANATE, PHLORIZIN, PIPERINE, PROGESTERONE, PYRROLE, QUERCETIN, RUTIN, SALSOLINOL, SEROTONIN, TAURINE, TESTOSTERONE, TRYPTOPHAN) SPRAY [BIOVEDA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Norepinephrine binds to alpha and beta adrenergic receptors, causing vasoconstriction and increased heart rate and contractility to treat hypotension. Ascorbic acid is added to stabilize norepinephrine and prevent oxidative degradation, potentially improving drug efficacy and shelf-life. This combination is used primarily in acute care settings for hemodynamic support.","oneSentence":"Norepinephrine acts as a sympathomimetic agent to increase blood pressure and cardiac output, while ascorbic acid (vitamin C) may enhance catecholamine stability and provide antioxidant support.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:40:59.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypotension in critical care / intensive care settings"},{"name":"Septic shock"},{"name":"Cardiogenic shock"}]},"trialDetails":[{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT03684213","phase":"PHASE1","title":"Local Antioxidant Therapy Vasoconstriction Effects in Different Races","status":"COMPLETED","sponsor":"The University of Texas at Arlington","startDate":"2018-10-15","conditions":"Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction","enrollment":22},{"nctId":"NCT04778605","phase":"","title":"Modulation of Endothelial Dysfonction Using Vitamin C in Septic Shock Patients","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-26","conditions":"Septic Shock","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":343,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Norepinephrine + Ascorbic Acid","genericName":"Norepinephrine + Ascorbic Acid","companyName":"The University of Texas at Arlington","companyId":"the-university-of-texas-at-arlington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norepinephrine acts as a sympathomimetic agent to increase blood pressure and cardiac output, while ascorbic acid (vitamin C) may enhance stability and bioavailability of the norepinephrine formulation. Used for Acute hypotension and shock (septic, cardiogenic, or hypovolemic), Maintenance of blood pressure in critically ill patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}